DFTX
What one share of Definium Therapeutics holds
Medicinal Chemicals and Botanical Products
We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.
Definium Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.47 |
|---|---|
| Cash and investments | $4.88 |
| Debt | $0.27 |
| Book value | $6.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1.91 | — | −$1.33 | — | $4.27 |
| 2021 | — | −$3.40 | — | −$1.67 | — | $5.39 |
| 2022 | — | −$1.84 | — | −$1.62 | — | $3.97 |
| 2023 | — | −$2.44 | — | −$1.64 | — | $1.90 |
| 2024 | — | −$1.54 | — | −$1.12 | — | $3.21 |
| 2025 | — | −$2.06 | — | −$1.47 | — | $3.36 |